Senti Biosciences, Inc. (NASDAQ:SNTI) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) have earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $8.50.

SNTI has been the subject of a number of research reports. Chardan Capital cut their price objective on Senti Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 28th.

Senti Biosciences Stock Performance

Shares of NASDAQ:SNTI opened at $0.84 on Thursday. Senti Biosciences has a 52-week low of $0.77 and a 52-week high of $5.10. The firm has a fifty day moving average of $0.93 and a 200 day moving average of $1.37. The firm has a market capitalization of $26.12 million, a PE ratio of -0.26 and a beta of 2.11.

Senti Biosciences (NASDAQ:SNTI) last released its earnings results on Friday, March 27th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.10). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $1.00 million. On average, sell-side analysts forecast that Senti Biosciences will post -14.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Senti Biosciences

Institutional investors have recently made changes to their positions in the business. Armistice Capital LLC bought a new position in shares of Senti Biosciences during the 2nd quarter valued at $1,883,000. Geode Capital Management LLC lifted its stake in Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares during the last quarter. Citadel Advisors LLC bought a new stake in Senti Biosciences in the third quarter worth $117,000. Virtu Financial LLC purchased a new stake in Senti Biosciences during the fourth quarter valued at about $46,000. Finally, Jane Street Group LLC purchased a new stake in Senti Biosciences during the fourth quarter valued at about $40,000. Hedge funds and other institutional investors own 25.70% of the company’s stock.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.